MacroGenics to Participate in Upcoming Investor Conferences
- MacroGenics' management will participate in upcoming investor conferences, including Citi's 18th Annual BioPharma Conference and H.C. Wainwright's 25th Annual Global Investment Conference.
- Scott Koenig, M.D., Ph.D., MacroGenics' President and CEO, will participate in panel discussions and provide a corporate presentation.
- Webcasts of the presentations will be available on the company's website for 30 days.
- None.
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:
- Citi’s 18th Annual BioPharma Conference (Boston). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in an ADC/Next Gen Panel Discussion on Wednesday, September 6, 2023, at 10:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.
- H.C. Wainwright’s 25th Annual Global Investment Conference (New York). Scott Koenig, M.D., Ph.D., will provide a corporate presentation on Monday, September 11, 2023, at 2:30 pm ET. MacroGenics’ management will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
